Journal article
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype
- Abstract:
- The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease-causing blood stage of malaria. However, the features of the human vaccine-induced antibody response that confer highly potent inhibition of malaria parasite invasion into red blood cells are not well defined. Here, we characterize 236 human IgG monoclonal antibodies, derived from 15 donors, induced by the most advanced PfRH5 vaccine. We define the antigenic landscape of this molecule and establish that epitope specificity, antibody association rate, and intra-PfRH5 antibody interactions are key determinants of functional anti-parasitic potency. In addition, we identify a germline IgG gene combination that results in an exceptionally potent class of antibody and demonstrate its prophylactic potential to protect against P. falciparum parasite challenge in vivo. This comprehensive dataset provides a framework to guide rational design of next-generation vaccines and prophylactic antibodies to protect against blood-stage malaria.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Supplementary materials, zip, 1.1MB, Terms of use)
-
(Preview, Version of record, pdf, 12.1MB, Terms of use)
-
- Publisher copy:
- 10.1016/j.cell.2024.06.015
Authors
- Publisher:
- Cell Press
- Journal:
- Cell More from this journal
- Publication date:
- 2024-07-25
- Acceptance date:
- 2024-06-10
- DOI:
- EISSN:
-
1097-4172
- ISSN:
-
0092-8674
- Pmid:
-
39059380
- Language:
-
English
- Keywords:
- Pubs id:
-
2018633
- Local pid:
-
pubs:2018633
- Deposit date:
-
2024-07-30
Terms of use
- Copyright holder:
- Barrett et al.
- Copyright date:
- 2024
- Rights statement:
- © 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Notes:
- This research was funded in part by the UK Medical Research Council (MRC) (grant numbers: MR/X012085/1 and MR/N013468/ 1). For the purpose of open access, the author has applied a CC BY public copyright license to any author-accepted manuscript (AAM) version arising from this submission.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record